Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (March 2022)
6 slides from Medical Developments International's investor presentation, Mar 3, 2022
Slide 1: Green Whistle gets the Green Light
Green Whistle gets the Green Light Investor Presentation Gordon Naylor – Chair Brent MacGregor - CEO 3 March 2022 - 10am AEDT Investors can register in advance for this presentation via the following link: https://us02web.zoom.us/webinar/register/WN_h_JHE2 2oQAirOoc7-7FDlQ 1
Slide 2: Disclaimer
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Removal of Full Clinical Hold allowing Phase III trial to commence
Removal of Full Clinical Hold allowing Phase III trial to commence The Journey So Far FDA Feedback on 1 March 2022 ▪ First request for FDA Meeting in February 2016 ▪ Penthrox Clinical Trial placed on Hold in August 2018 “We have completed the review of ▪ Formal Review (Type C) Meeting in January you
Slide 4: Trial Specifics
Trial Specifics Protocol – treatment of moderate to severe acute trauma pain in pre- hospital participants ▪ First patient enrolled late 2022 ▪ Expected study duration - 2 years ▪ 10 sites to be selected ▪ 200 patients in total ▪ Study costs circa A$12m 4
Slide 5: Key Takeaways
Key Takeaways • The lifting of the hold is unconditional • In anticipation we had commenced clinical trial preparations • We expect registration and launch in FY26 • Selfie is the intended launch product • A US launch will drive a second wave of expansion succeeding the current EU growth 5
Slide 6: Green Whistle gets the Green Light
Green Whistle gets the Green Light Investor Presentation 3 March 2022 - 10am AEDT 6
Medical Developments International — Investor Presentation (March 2022) on 6ix